[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fWnQf6u1Ids4Z35ZLNRaY0TJeyd9IFXninX9mMXxofOg":3},{"answer":4,"createTime":5,"id":6,"options":7,"origin":12,"question":19,"related":20,"source":24,"type":25},[],"2025-11-12 15:06:40",229092386,[8,9,10,11],"I期临床试验","IV期临床试验","II期临床试验","III期临床试验",{"count":13,"courseId":14,"courseImg":15,"courseName":16,"workId":17,"workName":18},22,"53e1d2ef4961cca8eea3e23969ad2cb9","https:\u002F\u002Ftihai-oss-cloud.itihey.com\u002Fimg\u002F03a579384a6dc297c89809b582fcc767.png","默认课程","work_46818848","第七章 药品研制巩固练习题","下列哪期临床试验是在药品上市后进行的",[21,26,35,44,53,62,71,80,87,97],{"answer":22,"createTime":5,"id":6,"options":23,"question":19,"source":24,"type":25},[],[8,9,10,11],"v1",0,{"answer":27,"createTime":5,"id":28,"options":29,"question":34,"source":24,"type":25},[],229092387,[30,31,32,33],"监督临床试验的药品监督管理部门","发起和管理临床试验的个人、组织或公司","进行临床试验的医院","负责临床研究的医生(研究者)","药物临床试验的申办者通常是指",{"answer":36,"createTime":5,"id":37,"options":38,"question":43,"source":24,"type":25},[],229092388,[39,40,41,42],"药品上市许可申请","新药临床试验申请","补充申请","药品生产申请","《药品注册管理办法》规定,完成临床试验后,申请人应当向国家药品监督管理局提交的,包含药物临床试验结果等重要资料的申请是",{"answer":45,"createTime":5,"id":46,"options":47,"question":52,"source":24,"type":25},[],229092389,[48,49,50,51],"药物的生产工艺和质量控制","药物的安全性评价,如遗传毒性、生殖毒性等","药物的疗效在广大人群中的验证","药物在医院的流通和使用","以下哪一项是药物非临床研究(GLP)主要关注的内容",{"answer":54,"createTime":5,"id":55,"options":56,"question":61,"source":24,"type":25},[],229092390,[57,58,59,60],"双盲试验","开放试验","三盲试验","单盲试验","为了消除主观偏见,使试验结果更为客观可靠,常采用"盲法"进行试验.其中,受试者、研究者、监查员均不知道治疗分配的是",{"answer":63,"createTime":5,"id":64,"options":65,"question":70,"source":24,"type":25},[],229092391,[66,67,68,69],"不需要记录使用情况","由研究者自行决定如何使用","可以提供给非临床试验的受试者使用","严格按照试验方案和随机编码进行","药物临床试验用药品的管理和使用,应当",{"answer":72,"createTime":5,"id":73,"options":74,"question":79,"source":24,"type":25},[],229092392,[75,76,77,78],"主要关注药代动力学参数","在健康志愿者中进行","样本量较小,通常在100例以下","是治疗作用确证阶段,需要大样本量","III期临床试验的主要特点是",{"answer":81,"createTime":5,"id":82,"options":83,"question":86,"source":24,"type":25},[],229092393,[84,40,85,39],"药品生产许可申请","药品经营许可申请","在药物研发中,申请人在药物临床试验实施前,应当提出哪个申请并获得批准",{"answer":88,"createTime":5,"id":89,"options":90,"question":96,"source":24,"type":25},[],229092394,[91,92,93,94,95],"受试者的权益保障","研究工作的实施","资料档案管理","仪器设备和实验材料","组织机构和人员","根据《药物非临床研究质量管理规范》(GLP),以下哪项不属于GLP主要规范的内容",{"answer":98,"createTime":5,"id":99,"options":100,"question":105,"source":24,"type":25},[],229092395,[101,102,103,104],"对于无行为能力的儿童,可以不获取知情同意直接进行试验","它应向受试者告知试验目的、过程、潜在风险与获益等关键信息","它是在试验结束后向受试者解释试验过程的文件","一旦签署,受试者在任何情况下都不能退出试验","关于"知情同意书",以下描述正确的是"]